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Abstract
TNFα, a mediator of hepatotoxicity in several animal models, is elevated in acute and chronic 
liver diseases. Therefore, we investigated whether hepatic injury and fibrosis due to bile duct 
ligation (BDL) would be reduced in TNFα knockout mice (TNFα−/−). Survival after BDL was 
60% in wild-type mice (TNFα+/+) and 90% in TNFα−/− mice. Body weight loss and liver to 
body weight ratios were reduced in TNFα−/− mice compared to TNFα+/+ mice. Following BDL, 
serum alanine transaminases (ALT) levels were elevated in TNFα+/+ mice (268.6 ± 28.2 U/L) 
compared to TNFα−/− mice (105.9 U/L ± 24.4). TNFα −/− mice revealed lower hepatic collagen 
expression and less liver fibrosis in the histology. Further, α-smooth muscle actin, an indicator for 
activated myofibroblasts, and TGF-β mRNA, a profibrogenic cytokine, were markedly reduced in 
TNFα−/− mice compared to TNFα+/+ mice. Thus, our data indicate that TNFα induces 
hepatotoxicity and promotes fibrogenesis in the BDL model.
Keywords
TNFα; Tumor necrosis factor α; Knockout mice; Bile duct ligation; BDL; Cholestasis; Liver 
fibrosis; TGF-β
Chronic cholestatic liver disorders are a serious clinical problem and often require liver 
transplantation due to cirrhosis [1]. The most common cholestatic liver diseases are primary 
biliary cirrhosis (PBC) and primary sclearosing cholangitis (PSC) [2]. Other conditions 
resulting in hepatic fibrosis and cirrhosis are alcohol consumption, viral infections, 
autoimmune and metabolic disorders, all leading to accumulation of extracellular matrix 
proteins, mainly collagen type I [3]. The hepatic stellate cell (HSC) is the main cell-type 
responsible for this hepatic collagen production [4].
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Tumor necrosis factor α (TNFα), a cytokine with diverse biological functions like 
cytotoxicity, inflammation, growth stimulation and immune modulation is elevated in most 
liver diseases [5]. For example, increased TNFα levels are found in patients with PBC [6], 
chronic viral hepatitis [7], fulminant hepatic failure [8], and negatively correlate with 
survival in patients with alcoholic liver disease [9]. In addition, TNFα levels are elevated in 
the serum of patients with alcoholic liver cirrhosis [10] and polymorphisms in the TNFα 
gene are associated with advanced fibrosis in alcoholic steatohepatitis [11]. Further, TNFα 
aggravates liver fibrosis induced by schistosomiasis in humans [12].
TNFα mediates liver injury in several animal models such as alcohol- or 
dimethylnitrosamine-induced liver injury [13,14] and plays an important role in perpetuation 
of HSC activation in vitro [15]. Further, TNFα induces liver failure or exacerbates liver 
injury following exposure to hepatotoxins such as carbon tetrachloride or amanitin [16,17]. 
On the other hand TNFα is required for liver regeneration after partial hepatectomy [18].
In experimental cholestasis induced by bile duct ligation (BDL) TNFα and IL-6 are elevated 
[19]. Further, hepatic macrophages from cholestatic livers exhibit high TNFα levels [20]. In 
a model of pulmonary fibrosis, TNFα receptor knockout mice were protected from the 
development of fibroproliferative lesions [21]. Also, hepatic injury following administration 
of the hepatotoxin carbon tetrachloride was inhibited in TNFα knockout mice [22]. This 
study was designed to investigate if hepatic injury and fibrosis due to BDL would be altered 
in TNFα−/− mice. Experimental cholestasis significantly decreased animal survival in wild-
type mice compared to TNFα−/− mice. In addition, BDL caused liver injury and fibrosis in 
TNFα+/+ mice, whereas pathology was largely prevented in TNFα−/− mice, indicating that 




A breeding colony of TNFα−/− mice, a kind gift of breeding pairs from Michael W. Marino 
Sloan-Kettering, New York [23] and TNFα+/+ mice (C57Bl/6) was established at the 
University of North Carolina at Chapel Hill. All animals were housed in a facility approved 
by the American Association for Accreditation of Laboratory Animal Care and received 
humane care in compliance with institutional guidelines. Animals were maintained under 
standard conditions.
Operative procedure and experimental protocol
TNFα−/− and TNFα+/+ mice were allocated randomly to four experimental groups and 
either bile duct ligation (BDL) or sham operations were performed as described previously 
[24]. On the day of sacrifice, mice were anesthetized, livers were harvested and blood 
samples were collected.
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Serum was stored at −20 °C until alanine aminotransferase (ALT) was analyzed by a 
standard quantitative colorimetric assay, according to the manufacturers’ protocol (Sigma, 
St. Louis, MO, USA).
Liver histology and histochemical detection of collagen
Liver sections were fixed in 10% formalin and embedded in paraffin; 10 μm sections were 
mounted on glass slides. Sections were deparaffinized and the slides were incubated for 30 
min in a solution of saturated picric acid containing 0.1% Sirius red and 0.1% fast green 
[24]. Image analysis was performed to quantify sirius red positive areas, as described [25].
Immunohistochemical staining for α-smooth muscle actin
Ten micron sections were deparaffinized, rehydrated and placed in phosphate buffered saline 
with 1% Tween 20. Immunohistochemistry was performed with a monoclonal primary 
mouse anti-α-smooth muscle actin antibody (Dako, Carpinteria, CA) and the EnVision kit 
(Dako, Carpinteria, CA). The primary antibody was diluted 1:200 with 1% bovine albumin 
(Sigma, St. Louis, MO) in PBS. The procedure followed the instructions outlined by the 
manufacturer. α-Smooth muscle actin positive cells were counted in 10 non-overlapping 
high power fields (hpf; magnification 400×).
RNase protection assay
Total RNA was isolated from liver tissue using RNA STAT 60 (Tel-Test Inc., Friendswood, 
TX). RNase protection assays were performed using the Ribo Quant multiprobe assay 
system (BD Biosciences, San Jose, CA) as described previously [25].
Western blot
Protein extraction and Western blotting were performed as described [26]. After 
electrophoresis the proteins were transferred onto nitrocellulose membranes and stained with 
0.5% Ponceau S to assess equal protein loading and transfer. Membranes were incubated 
with anti-collagen type I antibody (1:1000, Rockland, PA, USA) or anti-α-tubulin (1:1000, 
Santa Cruz, CA, USA), followed by incubation with the corresponding secondary 
antibodies. Immunodetected proteins were visualized using the enhanced chemiluminescent 
ECL assay kit ( Amersham Pharmacia Biotech, Piscataway, NJ).
Gelatin zymography
Twenty micrograms of whole liver cell extract were subjected to SDS–PAGE using a 0.1% 
gelatin containing polyacrylamide gel (Invitrogen, Carlsbad, CA). After electrophoresis the 
gel was exposed to renaturing buffer (2,5% Triton X-100) for 1 h, followed by developing 
buffer (50 mM Tris–HCl, pH 7.5 containing 0.15 M NaCl, 10 mM CaCl2, 0.02% NaN3) for 
24 h. Gels were stained with 0.1% Coomassie brilliant blue and destained with a solution of 
10% methanol and 10% acetic acid. MMP activity was determined by densitometric 
scanning of the 62 and 68 kD proteolytic bands, corresponding to MMP activity.
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Analysis of variance (ANOVA) or Tukey’s post-hoc tests were used for the determination of 
statistical significance, if appropriate. The Mann–Whitney rank sum test was used for 
statistical analysis of survival. P < 0.05 was selected as the level of significance. Data are 
expressed as means ± SEM.
Results
Body weight, liver to body weight ratios, survival and serum chemistry
Sham operation resulted in a body weight loss of about 10% in mice of both groups (Fig. 
1A). BDL caused a decrease in body weight in wild-type mice by about 20% in week one 
and 30% in week three. In contrast, body weight loss was blunted in TNFα−/− mice. 
However, there was only a statistical trend which did not reach the level of significance.
Liver to body weight ratios were 3.9% and 4.0% in control mice (Fig. 1B). BDL caused a 
liver enlargement to 6.9% in TNFα+/+ mice and 6.0% in TNFα−/− mice (P = 0.017).
Survival was 100% in both groups of sham-operated mice whereas only 60% of wild-type 
mice survived the experimental period of 3 weeks. In contrast, 90% of TNFα−/− mice 
survived the experimental period (Fig. 1C).
The average ALT levels of wild-type and TNFα−/− mice were 54.9 ± 26.1 U/L and 70.1 
± 30.8 U/L after sham operation (Fig. 1D). BDL significantly increased serum ALT levels to 
268.6 ± 28.2 U/L in TNFα+/+ mice but only 105.9 ± 24.4 U/L in TNFα−/− mice (P < 
0.004).
Histological and immunohistochemical evaluation of fibrosis
Sirius red fast green staining and image analysis were performed to detect extracellular 
matrix proteins (ECM). No staining was observed in livers of sham-operated mice (Fig. 2A, 
panel I: 0.8 ± 0.3% sirius red positive area; panel III: 1.0 ± 0.2% sirius red positive area). In 
contrast, strong staining was found in bile duct ligated wild-type mice compared to control 
mice (Fig. 2A, panel II: 4.1 ± 0.5% sirius red positive area; P < 0.001). Fibrosis with 
bridging was predominantly present in periportal areas. In addition, necrotic foci were 
detected in bile duct ligated wild-type mice (data not shown). However, BDL did not cause 
significant fibrotic or necrotic changes in the livers of TNFα−/− mice (Fig. 2A, panel IV: 1.5 
± 0.3% sirius red positive area; P < 0.001).
α-Smooth muscle actin (α-SMA) is marker for activated HSC. α-SMA positive cells could 
not be detected in livers of sham operated mice (Fig. 2B, panel I; III), while α-SMA positive 
cells were identified in wild-type mice after BDL, mainly in necrotic foci and around portal 
areas (Fig. 2B, panel II: 47.7 ± 16.9 cells/hpf; P < 0.001). In contrast, positive staining was 
decreased in TNFα−/− mice after BDL (Fig. 2B, panel IV: 11.5 ± 6.2 cells/hpf; P < 0.001).
Evaluation of collagen expression
Collagen I protein expression was evaluated by Western blotting (Fig. 2C). In sham operated 
animals collagen I was not detectable. BDL resulted in a strong increase in the expression of 
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collagen I in TNFα+/+ mice, while collagen I protein was not detectable in TNFα−/− mice. 
α-Tubulin served as a control to ensure equal loading (Fig. 2C, lower panel).
TGF-β mRNA expression and MMP activity
TGF-β mRNA levels were analyzed by RNase protection assay. TGF-β mRNA was 
undetectable in livers of sham operated mice. BDL significantly increased TGF-β mRNA 
levels in both wild-type and TNFα−/− mice but the increase was less in TNFα−/− mice, 
indicating a decrease in the profibrogenic response in TNFα−/− mice after BDL (Fig. 2D).
To determine the activity of matrix metalloproteinase 2 and 9 (MMP-2, −9), gelatin 
zymography was performed (Fig. 2E). MMP activity was absent in mice after sham 
operation. MMP activity was clearly increased in TNFα+/+ and TNFα−/− mice after BDL, 
revealing a band at 68 kDa corresponding to MMP-2. No differences in MMP activity were 
found between both BDL groups.
Discussion
TNFα has many functions in hepatic injury. On the one hand, it plays an important role in 
liver regeneration [18], but it is also associated with liver injury in many experimental 
models [27] and human diseases [6,8,9].
Since experimental models showed that TNFα receptor knockout mice were protected from 
pulmonary fibrosis and carbon tetrachloride-induced liver injury [21,22,28] we wanted to 
test if liver injury and fibrosis caused by experimental cholestasis are attenuated in TNFα−/− 
mice. Indeed, we found that fibrosis and liver injury were reduced significantly in TNFα−/− 
mice following BDL-induced liver injury.
We chose the BDL model, because TNFα is elevated in the serum of jaundiced mice and 
concentrations of the soluble TNF receptor negatively correlate with mortality in this model 
[19,29]. In line with these data, our study showed a clear decrease of survival rates in TNFα
+/+ mice, while survival was 90% in TNFα−/− mice, indicating a significant role of TNFα 
in the pathophysiological process in the BDL model. Moreover, body weight loss was less 
pronounced in absence of TNFα, confirming the cachectic effect of TNFα in the BDL 
model, previously attributed to TNFα as cachectin [30,31].
How does absence of TNFα protect the liver from hepatic injury and fibrosis due to BDL? 
Obstructive jaundice produces high levels of TNFα in macrophage-rich organs and 
peritoneal macrophages in response to LPS [32]. Hepatic macrophages, i. e. Kupffer cells 
(KC), largely contribute to liver fibrosis, since depletion of KC using GdCl3 prevents HSC 
activation and the development of cirrhosis in the rat [33].
BDL also leads to accumulation of hydrophobic bile acids which cause oxidative stress in 
the liver [34,35]. Oxidative stress can induce TGF-β in several cell types [36,37]. In the 
BDL model oxidative stress can increase TNFα and IL-6 concentrations via NFκB 
activation in KC leading to enhanced TGFβ and collagen expression [20,38]. Conclusively, 
we showed decreased fibrosis and less hepatic collagen expression in mice lacking TNFα, 
while wild-type mice showed strong fibrotic changes after BDL. Since TNFα is able to 
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induce profibrogenic signals in KC, a possible mechanism could be that the absence of 
TNFα leads to a reduction of cytokines, such as TGFβ, from KC [20,38].
TGFβ is one of the main profibrogenic factors involved in collagen synthesis and widely 
used to analyze the fibrogenic response [39]. Here, we demonstrate that TGFβ mRNA levels 
were significantly diminished in TNFα−/− mice after BDL, previously described in carbon 
tetrachloride-induced liver fibrosis [22,28]. Since TGFβ is upregulated in liver fibrosis and 
known to cause HSC proliferation and production of collagen [40,41], TNFα leads to 
upregulation of TGFβ in the BDL model thereby amplifying fibrosis.
Hepatocytes contribute to the profibrogenic response, because signals from hepatocytes 
undergoing oxidative stress can increase proliferation and collagen synthesis in HSC [42]. 
TNFα has cytotoxic effects so that an effect of TNFα on hepatocytes cannot be ruled out 
[43]. Massive hepatocyte cell death and necrosis, followed by macrophage activation, 
subsequently leads to excessive repair and fibrosis, induced by stimuli from different hepatic 
cell-types [4]. Indeed, BDL significantly increased ALT values in serum of TNFα+/+ mice 
indicating parenchymal liver cell damage, while ALT release in TNFα−/− mice was 
attenuated after BDL. We conclude that the absence of TNFα results in decreased 
parenchymal cell damage and attenuation of liver fibrosis.
TNFα has direct effects on HSC. For example, TNFα can induce transcription factors only 
in activated, but not in quiescent HSC [15]. Moreover, TNFα activates HSC by stimulating 
MAP-kinase activity and increased AP-1 binding [44,45]. In the current study, HSC 
activation, shown by expression of α-SMA, was clearly decreased in TNFα−/− mice after 
BDL. Data supporting this showed that inhibition of TNFα-induced MAP kinase activation 
also reduced α-SMA expression in HSC [44]. Thus, TNFα influences HSC activation in the 
BDL model.
Since TGFβ and TNFα can upregulate TIMP expression, thereby enhancing liver fibrosis 
[46], we analyzed collagenase activity by gelantin zymography. However, no differences in 
MMP activity were found in the BDL groups, indicating that TNFα does not interfere with 
collagenase activity in this model.
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Effect of BDL on body weight, liver to body weight ratios, survival and serum chemistry in 
TNFα+/+ or TNFα−/− mice. (A) Wild-type (black symbols) or TNFα−/− (white symbols) 
mice underwent BDL (circles) or sham operation (squares) as described. Body weights (n = 
6–8) were measured weekly and normalized to percent of initial weight. Data represent 
mean ± SEM. aP < 0.05 compared with mice receiving sham operation by two-way ANOVA. 
(B) Body and liver weights (n = 6–8) were determined at sacrifice. Data are presented as 
mean ± SEM. aP < 0.05 compared with mice receiving sham operation. bP < 0.05 compared 
with BDL wild-type mice by two-way ANOVA with Tukey’s post-hoc test. (C) Survival was 
determined after 3 weeks (n = 6–8). aP < 0.05 compared with mice receiving sham operation 
by Mann–Whitney rank sum test. (D) Alanine aminotransferase (ALT) levels (n = 5–8) were 
determined as described in methods. Data presented are mean ± SEM. Two-way ANOVA 
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with Tukey’s post-hoc test was used for determination of statistical differences. aP < 0.05 
compared with mice receiving sham operation. bP < 0.05 compared with TNFα+/+ mice 
receiving BDL.
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Evaluation of hepatic fibrosis and collagen expression after BDL in TNFα+/+ and TNFα−/− 
mice. (A) Sirius red fast green staining of mouse livers following 3 weeks of BDL. Sham 
operated TNFα+/+ (panel I) and TNFα−/− mice (panel III). BDL in TNFα+/+ (panel II) and 
TNFα−/− mice (panel IV). Magnification 100×. Representative micrographs are shown. 
Quantification of sirius red positive areas using image analysis (panel V). aP < 0.05 
compared with mice receiving sham operation. b p < 0.05 compared with TNFα+/+ mice 
receiving BDL. (B) Immunohistochemical staining for α-smooth muscle actin (α-SMA) 
after 3 weeks of BDL. Representative micrographs. α-SMA staining after sham operation in 
TNFα+/+ (panel I) and TNFα−/− mice (panel III); effect of BDL on α-SMA staining in 
TNFα+/+ (panel II) and TNFα−/− mice (panel IV). Quantification of α-SMA positive cells 
(panel V). aP < 0.05 compared with mice receiving sham operation. bP < 0.05 compared 
with TNFα+/+ mice receiving BDL. (C) Expression of collagen I protein (105 kDa, upper 
panel) and α-tubulin (55 kDa, lower panel) in control mice (lane 1-2), TNFα+/+ mice (lane 
3–5) and TNFα−/− mice (lane 6–8) after BDL using Western blot analysis. (D) TGF-β 
mRNA levels by RNase protection assay in TNFα+/+ and TNFα−/− mice after sham 
operation (lane 1–4) or BDL (lane 5–8). Representative autoradiogram. (E) Collagenase 
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activity assessed by gelatin zymography in TNFα+/+ and TNFα−/− mice after sham 
operation (lane 1 and 2) or BDL (lane 3–6). Representative zymogram.
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